Bortezomib for the treatment of multiple myeloma patients
Green C, Bryant J, Takeda A, Cooper K, Clegg A, Smith A, Stephens M
Record ID 32011001402
English
Authors' recommendations:
The ERG suggests that the cost-effectiveness results presented in the manufacturer’s submission may underestimate the cost per life-year gained for bortezomib therapy (versus HDD) when potential UK practice and scenarios are considered.There is no standard treatment for relapsed multiple myeloma patients, which makes assessing the effectiveness and cost-effectiveness of new treatments problematic in terms of the individuality of treatment protocols and which comparators to use. It would be useful for future trials to reflect current practice but this may be difficult as it is a quickly developing area in which clinicians are eager to have new treatments options for patients who do not easily fit into stereotypical groups.
Details
Project Status:
Completed
Year Published:
2009
URL for published report:
http://www.hta.ac.uk/1637
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Bortezomib
- Randomized Controlled Trials as Topic
- Technology Assessment, Biomedical
- Antineoplastic Agents
- Boronic Acids
- Multiple Myeloma
- Pyrazines
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.